GSK has halted all shipments of ARIXTRA Starter Kits containing the Triad For important product information, log onto Arixtra mg/ ml solution for injection, pre-filled syringe. 2. .. Detailed information on this medicinal product is available on the website of the European . Arixtra is a medicine that helps prevent blood clots from forming in the blood This medicinal product contains less than 23 mg of sodium in each dose and.
|Published (Last):||28 March 2017|
|PDF File Size:||9.28 Mb|
|ePub File Size:||2.82 Mb|
|Price:||Free* [*Free Regsitration Required]|
Anticoagulant effects may persist for 2—4 days following discontinuance of therapy in patients with normal renal function i.
Increased risk of hemorrhage; closely monitor for signs and symptoms of bleeding. Postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: Active major bleeding, bacterial endocarditis, or thrombocytopenia associated with a positive in vitro test for antiplatelet antibody HIT in the presence of the drug.
Subscribe to receive email notifications whenever new articles are published. Optimal timing between administration arixxtra fondaparinux and neuraxial procedures not known. Arixtra fondaparinux sodium injection prescribing information.
The pharmacokinetics of fondaparinux sodium in healthy volunteers. Used for extended prophylaxis i. Used in patients undergoing PCI to prevent thrombus formation during the procedure; however, should not be used as the sole anticoagulant to support PCI. Bounameaux, H, Perneger T.
If coadministration is essential, monitor patients closely 1 Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. Postoperative wound infection, postoperative hemorrhage, fever, surgical site reaction, anemia, hypertension, pneumonia, vomiting. Monitor frequently for manifestations of neurologic impairment and treat urgently if neurologic compromise noted.
Discontinue oral anticoagulants prior to initiation of fondaparinux 1 Anticoagulation results from rapid inhibition of factor Xa by antithrombin III informatiom to fondaparinux about fold greater than prescriving activity. Initiate concurrent warfarin as soon as possible, 1 usually within 72 hours of fondaparinux injection; 1 20 ACCP recommends initiating warfarin simultaneously on the first day of fondaparinux treatment.
Binds selectively to antithrombin III; unable to inactivate thrombin. ACCP recommends fondaparinux as an option for thromboprophylaxis in acutely ill, hospitalized medical patients at increased risk of thrombosis.
Prevention of VTE in informstion surgery patients: If PCI is performed while a patient is receiving fondaparinux, administer an additional anticoagulant with anti-factor IIa antithrombin activity because of the risk of catheter thrombosis.
Avoid concomitant use of drugs that increase risk of bleeding unless essential for management of underlying condition e. Lovenox enoxaparin sodium injection prescribing information. Has been administered at an initial dose of 2.
Efficacy and safety of fondaparinux versus enoxaparin in patients with presccribing coronary syndromes undergoing percutaneous coronary intervention: Usual duration of therapy is arictra days, although up to 26 days of treatment has been used. Epidural or spinal hematoma reported with concurrent use of anticoagulants e. Initial parenteral anticoagulants with established efficacy in patients with NSTE ACS include enoxaparin, heparin, bivalirudin only in patients managed with an early invasive strategyand fondaparinux.
Prevention of VTE in nonorthopedic surgical patients: Do not administer earlier than 6—8 hours after surgery because of increased risk of major bleeding. If fondaparinux therapy is to be continued after hospital discharge, importance of instructing patient on proper administration of the drug, including injection technique.
A randomized double-blind comparison.
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip- fracture surgery. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Bridgewater, NJ; Jul.
Hull R, Pineo G. Administer by sub-Q injection into fatty tissue, alternating injection sites daily e. J Am Coll Cardiol. Importance of patients informing clinicians including dentists that they are receiving fondaparinux therapy before scheduling any invasive procedures.
Arixtra Monograph for Professionals –
Print this page Add to My Med List. In healthy adults, distributes mainly in blood and only to a minor extent in extravascular fluid.
A randomized double-blind trial. Some packaging components e. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Clin Appl Thromb Hemost.
Arixtra Rating 5 User Reviews 8. Importance of discontinuing fondaparinux and immediately contacting a clinician if a serious allergic reaction e. Research Triangle Park, NC: Discontinue oral anticoagulants prior to initiation of fondaparinux 1 40 If coadministration is essential, monitor patients closely 1 We comply with the HONcode standard for trustworthy health information – verify here.
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.